Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
New England Journal of Medicine · 2023
DOI: 10.1056/nejmoa2211031 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Flor M Muñoz und 38 weiteren Autor:innen. Beteiligte Einrichtung: From Texas Children's Hospital, Baylor College of Medicine, Houston (F.M.M.), and the University of Texas Medical Branch, Galveston (J.Z., X. Xie, P.…. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sponsored by BioNTech, funded by Pfizer.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children. METHODS: We conducted a phase 1 dose-finding study and are conducting an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age. We present results for children 6 months to less than 2 years of age and those 2 to 4 years of age through the data-cutoff dates (April 29, 2022, for safety and immunogenicity and June 17, 2022, for efficacy). In the phase 2-3 trial, participants were randomly assigned (in a 2:1 ratio) to receive two 3-μg doses of BNT162b2 or placebo. On the basis of preliminary immunogenicity results, a third 3-μg dose (≥8 weeks after dose 2) was administered starting in January 2022, which coincided with the emergence of the B.1.1.529 (omicron) variant. Immune responses at 1 month after doses 2 and 3 in children 6 months to less than 2 years of age and those 2 to 4 years of age were immunologically bridged to responses after dose 2 in persons 16 to 25 years of age who received 30 μg of BNT162b2 in the pivotal trial. RESULTS: During the phase 1 dose-finding study, two doses of BNT162b2 were administered 21 days apart to 16 children 6 months to less than 2 years of age (3-μg dose) and 48 children 2 to 4 years of age (3-μg or 10-μg dose). The 3-μg dose level was selected for the phase 2-3 trial; 1178 children 6 months to less than 2 years of age and 1835 children 2 to 4 years of age received BNT162b2, and 598 and 915, respectively, received placebo. Immunobridging success criteria for the geometric mean ratio and seroresponse at 1 month after dose 3 were met in both age groups. BNT162b2 reactogenicity events were mostly mild to moderate, with no grade 4 events. Low, similar incidences of fever were reported after receipt of BNT162b2 (7% among children 6 months to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Texas Children's Hospital, Baylor College of Medicine, Houston (F.M.M.), and the University of Texas Medical Branch, Galveston (J.Z., X. Xie, P.-Y.S.); Peninsula Research Associates, Rolling Hills Estates (L.D.S.),…
ORCID-Profile: Kena A Swanson
Förderung
- Sponsored by BioNTech, funded by Pfizer
Zitieren
APA
Muñoz, F. M., Sher, L. D., Sabharwal, C., Gurtman, A., Xu, X., Kitchin, N., Lockhart, S., Riesenberg, R., Sexter, J. M., Czajka, H., Paulsen, G. C., Maldonado, Y., Walter, E. B., Talaat, K. R., Englund, J. A., Sarwar, U. N., Hansen, C., Iwamoto, M., Webber, C., …, & C4591007 Clinical Trial Group (2023). Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2211031
Vancouver
Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. New England Journal of Medicine. 2023. doi:10.1056/nejmoa2211031
BibTeX
@article{Muoz2023,
author = {Muñoz, Flor M and Sher, Lawrence D and Sabharwal, Charu and Gurtman, Alejandra and Xu, Xia and Kitchin, Nicholas and Lockhart, Stephen and Riesenberg, Robert and Sexter, Joanna M and Czajka, Hanna and Paulsen, Grant C and Maldonado, Yvonne and Walter, Emmanuel B and Talaat, Kawsar R and Englund, Janet A and Sarwar, Uzma N and Hansen, Caitlin and Iwamoto, Martha and Webber, Chris and Cunliffe, Luke and Ukkonen, Benita and Martínez, Silvina N and Pahud, Barbara A and Munjal, Iona and Domachowske, Joseph B and Swanson, Kena A and Ma, Hua and Koury, Kenneth and Mather, Susan and Lu, Claire and Zou, Jing and Xie, Xuping and Shi, Pei-Yong and Cooper, David and Türeci, Özlem and Şahin, Uğur and Jansen, Kathrin U and Gruber, William C and C4591007 Clinical Trial Group, C4591007 Clinical Trial Group},
title = {Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age},
journal = {New England Journal of Medicine},
year = {2023},
doi = {10.1056/nejmoa2211031}
}
EUVIMED